The Effects of Yeast Selenium on CD4 T Cell Count of Non-Institutionalized HIV type 1 Positive Orphan Children at Orongo Widows and Orphans in Kisumu Kenya
Loading...
Date
2014-05
Authors
Kabiru, Ephantus W.
Otieno, S.B.
Were, F.
Waza, K.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: Multi drug resistance HIV has emerged rendering the current conventional treatment of HIV
ineffective. There is a need for new treatment regime which is cheap, effective and not prone to resistance
development by HIV.
Methods: In randomized clinical study of 68 HIV positive children 3 – 15 years to asses the efficacy of yeast
selenium in HIV/AIDS patients, 50μ yeast selenium was administered to 34 children while in matched control of
34 were put on placebo. Blood samples of the both groups which were taken every 3 months intervals up to 6
months, were analyzed by ELISA for CD4T cells, the data was analyzed by SPSS version 16.
Results: No significant difference in age { χ2 (1, 62) =0.03, p =0.853}, cause of morbidity between test and
controls {χ2 ( 1, 65) = 5.87, p= 0.015} and on condition of foster parents {χ2 ( 1,63) = 5.57, p= 0.0172} was
observered. Children on selenium showed progressive improvement of WAZ and significant difference at six
months{F (5,12) = =5.758, P=0.006}, and weight gain of up to2.5kilograms in six months, and significant CD4 T
cell count increase t = -2.943,p< 0.05 compared to matched controls t = -1.258 p> 0.05. CD4 T cell count
increased among all age groups on test 3-5years (+ 267.1),5-8 years( +200.3) 9-15 years (+71.2) cells/mm3
and in matched controls a decrease 3-5 years(-71),5-8 years (-125) and 9-13years(-10.1)cells/mm3 . No
significant difference in CD4 T cell count between girls {F (2, 32) = 1.531 p= 0.232} and between boys {F (2, 49)
= 1.040, p= 0.361} on test and between boys and girls {F (5, 81) = 1.379, p= 0.241} on control was observed.
Conclusion: From this study it can be concluded that administration of yeast Selenium led to slowing the
progress of HIV 1 in children from WHO clinical stage I by improving CD4 T cell count and hence the immunity.
Description
Journal article
Keywords
Citation
International Journal of Applied Science and Technology Vol. 4, No. 3; May 2014